Dr. Ken H. Young is a tenured full professor and director in the Division of Hematopathology at the Duke University Medical Center and Duke Cancer Center. He is a clinically oriented diagnostic physician with extensive expertise in the diagnosis of hematologic cancers, including tumors of the bone marrow, lymphoid tissue, spleen, and premalignant hematologic conditions. His contributions to the hematology field include the development of novel technologies, as well as molecular and genetic biomarkers for classification in blood cancer and lymphoid diseases. Dr. Young has specialized in the diagnosis of hematological disorders, including acute and chronic leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, B-cell and T-cell lymphomas, Hodgkin lymphoma, cutaneous and orbital lymphomas, and benign bone marrow and lymph node disorders. In his clinical translational and research program, Dr. Young focuses on molecular mechanisms of tumor progression, cell-of-origin, molecular and genetic biomarkers, and novel therapeutic strategies in lymphoma, myeloma, and leukemia. His goal is to explore and identify genetic and nongenetic biomarkers, including p53, Myc, Bcl-2, and Bcl-6 genes, alone or in combination with other abnormalities in DLBCL/HGBCL, that predict cancer prognosis and susceptibility. Honors and Awards 2019-Present National Institute of Health/National Cancer Institute (NIH/NCI) Lymphoma Award 2012-2018 NIH/NCI Myeloma Specialized Programs of Research Excellence (SPORE) Award NIH/NCI Lymphoma Specialized Programs of Research Excellence (SPORE) Award MD Anderson Sister Hospital Global Academic Program Award 2007-2011 NIH/NCI Myeloma Research Grant Award Lymphoma and Leukemia Society Award Paul Paulson Lymphoma Award Publications: (limit to 5 publications per speaker) 1. Young KH, et al. Diffuse large B-cell lymphoma. In: Orazi A, Weiss LM, Foucar K, Knowles DM, eds. Neoplastic Hematopathology. Philadelphia, PA, USA: Lippincott Willaims & Wilkins. 2014, pp502-565. 2. Miao Y and Young KH, et al. Genetic alterations and their clinical implications in DLBCL. Nat Rev Clin Oncol. 2019;16:634-652. 3. Yu L and Young KH, et al. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood. 2017;129:1658‐1668. 4. Xu-monette ZY and Young KH. Immunotherapy and Immune Checkpoint Pathway. Blood. 2019 5. Yu L and Young KH, et al. Novel Clinical Predictive Model of HIV- and HHV-8-negative Castleman disease. The Oncologist. 2020 In Press.